Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study.
Ryuki ChataniYugo YamashitaTakeshi MorimotoNao MuraokaMichihisa UmetsuYuji NishimotoTakuma TakadaYoshito OgiharaTatsuya NishikawaNobutaka IkedaKazunori OtsuiDaisuke SuetaYasuhiro TanabeMasaaki ShojiAyumi ShikamaYutaka HosoiYasuhiro TanabeKengo TsukaharaNaohiko NakanishiKitae KimSatoshi IkedaKazunori MushiakeKazushige KadotaKoh OnoTakeshi KimuraPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
A 12-month edoxaban regimen for cancer-associated isolated distal DVT was consistently superior to a 3-month regimen, across the edoxaban doses for the thrombotic risk. However, caution was suggested for the standard dose of edoxaban due to the potential for an increased risk of bleeding with prolonged anticoagulation therapy.